Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least squares (OLS)...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The evolution of nonlinear mixed effects modeling in pharmacometrics: toward AI-based variational autoencoders.

Journal of pharmacokinetics and pharmacodynamics·2026
Same author

Theoretical and Numerical Investigation of the Consistency of Model Comparisons in Pharmacometrics.

The AAPS journal·2026
Same author

Evaluation of adalimumab tapering regimens in children and adolescents with juvenile idiopathic arthritis in remission: a simulation study.

Pediatric rheumatology online journal·2026
Same author

Predictive AI in Clinical Pharmacology: A Call to Action to Develop Robust Benchmarking Practices.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Redefining Parameter Estimation and Covariate Selection via Variational Autoencoders: One Run Is All You Need.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Analysis for Clazakizumab in Patients With End-Stage Kidney Disease Undergoing Dialysis.

Clinical and translational science·2025

Related Experiment Video

Updated: Jun 25, 2026

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data
09:47

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data

Published on: December 15, 2023

Automated Pharmacometric Model Development by Leveraging Low-Dimensional Neural ODEs and LASSO Regression.

Dominic Stefan Bräm1, Bernhard Steiert2, Britta Steffens1

  • 1Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel UKBB, Basel, Switzerland.

CPT: Pharmacometrics & Systems Pharmacology
|June 24, 2026
PubMed
Summary

This study introduces an automated approach combining neural ordinary differential equations (NODEs) and LASSO regression to develop interpretable pharmacokinetic/pharmacodynamic (PK/PD) models, reducing manual effort in pharmacometrics (PMX). The NODE-LASSO method efficiently generates mechanism-based structures from data, enhancing model-informed drug development.

Keywords:
LASSO regressionautomatic modelingmachine learningneural ordinary differential equationspharmacometrics

Related Experiment Videos

Last Updated: Jun 25, 2026

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data
09:47

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data

Published on: December 15, 2023

Area of Science:

  • Pharmacometrics
  • Machine Learning
  • Pharmacokinetics/Pharmacodynamics

Background:

  • Current pharmacometrics (PMX) model development is manual, iterative, and resource-intensive.
  • Existing automated methods still rely on iterative processes and goodness-of-fit criteria for model selection.
  • Neural ordinary differential equations (NODEs) show potential for complex PK/PD dynamics but lack interpretability.

Purpose of the Study:

  • To develop an automated approach for generating interpretable structural models in pharmacometrics.
  • To combine the data-driven capabilities of NODEs with the interpretability of mechanistic models.
  • To reduce the manual effort and time required for pharmacometric model development.

Main Methods:

  • Integration of neural ordinary differential equations (NODEs) with least absolute shrinkage and selection operator (LASSO) regression.
  • Leveraging LASSO's feature selection to automatically propose structural models based on NODE-learned dynamics.
  • Application and validation of the NODE-LASSO approach on neonatal weight, bi-exponential PK, and warfarin PK/PD data.

Main Results:

  • The automated NODE-LASSO approach successfully recovered meaningful, mechanism-based structures from data.
  • Demonstrated applicability across diverse scenarios including physiological and drug-specific PK/PD.
  • Significantly reduced the need for extensive iterative and manual model development.

Conclusions:

  • The NODE-LASSO approach offers a resource-efficient and interpretable modeling strategy for pharmacometrics.
  • This method has strong potential for application in model-informed drug development and clinical research.
  • Automating the proposal of mechanistic structures enhances the utility of data-driven models in PMX.